MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze GRFS →
    • FindStock Picks / Stock Screener
    • Value · GRFSIntrinsic Value Calculator
    • Invest · GRFSInvestment Case
    • Hold · GRFS5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
GRFS

GRFS

Grifols, S.A.

$8.69
-0.11
 (-1.25%)
Exchange:  NASDAQ
Market Cap:  7.352B
Shares Outstanding:  680.575M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Drug Manufacturers – GeneralView industry performance
   
CEO:  Jose Ignacio Abia Buenache
Full Time Employees:  25258
Address: 
Parque Empresarial Can Sant Joan
Barcelona
CT
8174
ES
Website:  https://www.grifols.com
Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.

Click to read more…

Revenue Segmentation

Revenue by type

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
GRGRFS logoGRFSGrifols, S.A.7.4B16.29.15.5%
OGOGN logoOGNOrganon & Co.3.7B17.64.24.7%
AMAMRN logoAMRNAmarin Corporation plc235.4M——-5.3%
CTCTOR logoCTORCitius Oncology, Inc.84.8M——-47.8%
SCSCLX logoSCLXScilex Holding Company10.1M——162.6%
BIBIIB logoBIIBBiogen Inc.37.5B10720.32.8%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/09 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue6,591,9777,212,3827,227,047.987
Gross Profit2,483,4822,794,5382,579,990.815
EBITDA1,169,5031,484,4641,623,300.250
Operating Income782,3171,192,0151,187,218.408
Net Income42,318156,920386,134.142

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets21,441,05421,405,24119,749,590.896
Total Liabilities13,468,56912,798,21612,133,833.580
Total Stockholders Equity5,827,1665,883,7275,268,756.636
Total Debt10,117,43910,085,6198,740,278.509
Cash and Cash Equivalents529,577979,780824,648.875

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow208,283902,1681,005,677.730
Capital Expenditure-295,420-371,367-254,541.161
Free Cash Flow-87,137530,801751,136.568
Net Income59,315443,996386,134.142
Net Change in Cash-18,402450,203-38,845.004

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)9,544,888.586Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)9,673,916.886Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)9,607,240.855Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)2,501,795.206Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)2,527,088.486Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)2,514,019.717Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)1,134,580.298Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)1,154,561.989Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)1,144,237.662Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)1,698,498.762Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)1,721,459.156Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)1,709,594.256Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)1.680Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)1.700Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)1.670Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)2Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
7.802B  ?P/S
 (TTM)
: 
0.93
?Net Income
 (TTM)
: 
169.739M  ?P/E
 (TTM)
: 
16.18
?Enterprise Value
 (TTM)
: 
15.84B  ?EV/FCF
 (TTM)
: 
21.11
?Dividend Yield
 (TTM)
: 
0.71%  ?Payout Ratio
 (TTM)
: 
17.58%
?ROE
 (TTM)
: 
8.83%  ?ROIC
 (TTM)
: 
5.5%
?Net Debt
 (TTM)
: 
8.513B  ?Debt/Equity
 (TTM)
: 
1.6
?P/B
 (TTM)
: 
1.37  ?Current Ratio
 (TTM)
: 
2.33

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
9.06Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates GRFS intrinsic value between $20.13 – $24.76 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate GRFS Intrinsic Value

Common questions about GRFS valuation

Is Grifols, S.A. (GRFS) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Grifols, S.A. (GRFS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is GRFS a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether GRFS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is GRFS’s P/E ratio?

You can see GRFS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for GRFS?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is GRFS a good long-term investment?

Whether GRFS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Grifols, S.A.

  • Grifols, S.A. intrinsic value calculatorEstimate what the business is worth
  • Grifols, S.A. 5-year outlookWhat has to go right, and what could go wrong
GRFS

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-1.25
MarketSnap

Trading Metrics:

Open: 8.78   Previous Close: 8.8
Day Low: 8.69   Day High: 8.78
Year Low: 6.96   Year High: 9.77
Price Avg 50: 7.73   Price Avg 200: 7.98
Volume: 312662   Average Volume: 628584

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Grifols: Plasma, Profits, And Recovery Gathering Momentum
03-11-2026 13:19
Grifols: Plasma, Profits, And Recovery Gathering Momentum
Grifols, S.A. (NASDAQ:GRFS) Sees Significant Increase in Short Interest
16-10-2026 02:43
Grifols, S.A. (NASDAQ:GRFS) Sees Significant Increase in Short Interest
GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?
24-09-2026 12:41
GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now?
Grifols says Canada plasma license suspension has no impact
24-09-2026 05:18
Grifols says Canada plasma license suspension has no impact
Grifols: Better Plasma Economics Can Unlock A Discounted Equity
16-09-2026 21:33
Grifols: Better Plasma Economics Can Unlock A Discounted Equity
GRFS or SDZNY: Which Is the Better Value Stock Right Now?
08-09-2026 12:40
GRFS or SDZNY: Which Is the Better Value Stock Right Now?

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze GRFS →
    • FindStock Picks / Stock Screener
    • Value · GRFSIntrinsic Value Calculator
    • Invest · GRFSInvestment Case
    • Hold · GRFS5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.